Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
3.940
+0.040 (1.03%)
Sep 2, 2026, 4:00 PM EDT - Market closed
Protara Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 17.08 | 49.66 | 162.8 | 39.59 | 24.13 | 35.72 |
Short-Term Investments | 125.42 | 105.9 | 7.49 | 25.99 | 60.24 | 55.51 |
Cash & Short-Term Investments | 142.49 | 155.55 | 170.29 | 65.58 | 84.37 | 91.23 |
Cash Growth | 16.59% | -8.65% | 159.67% | -22.27% | -7.52% | -45.89% |
Other Receivables | 1.28 | 1.26 | - | 0.24 | 0.49 | 0.63 |
Receivables | 1.28 | 1.26 | - | 0.24 | 0.49 | 0.63 |
Prepaid Expenses | 0.66 | 0.7 | 0.93 | 0.89 | 0.59 | 0.53 |
Other Current Assets | 1.72 | 1.99 | 0.94 | 1.99 | 0.7 | 0.72 |
Total Current Assets | 146.15 | 159.5 | 172.16 | 68.71 | 86.15 | 93.11 |
Property, Plant & Equipment | 3.92 | 3.93 | 5.28 | 6.56 | 7.87 | 8.89 |
Long-Term Investments | 19.36 | 42.34 | - | - | 17.89 | 39.47 |
Goodwill | - | - | - | - | - | 29.52 |
Long-Term Deferred Charges | 5.85 | 2.93 | 3.25 | 2.66 | 0.08 | - |
Other Long-Term Assets | 0.82 | 0.77 | 0.77 | 1.03 | 1.31 | 1.61 |
Total Assets | 176.09 | 209.47 | 181.45 | 78.95 | 113.29 | 172.6 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 4.66 | 3.47 | 4.43 | 2.43 | 1.59 | 0.95 |
Accrued Expenses | 7.37 | 6.23 | 5.41 | 2.73 | 3.24 | 2.49 |
Current Portion of Leases | 1.29 | 1.24 | 1.12 | 0.98 | 0.92 | 0.86 |
Total Current Liabilities | 13.32 | 10.94 | 10.96 | 6.15 | 5.74 | 4.3 |
Long-Term Leases | 1.46 | 2.12 | 3.36 | 4.48 | 5.47 | 6.38 |
Total Liabilities | 14.78 | 13.06 | 14.32 | 10.63 | 11.21 | 10.68 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.06 | 0.05 | 0.04 | 0.01 | 0.01 | 0.01 |
Additional Paid-In Capital | 503.48 | 498.69 | 412.08 | 268.73 | 262.72 | 256.13 |
Retained Earnings | -341.87 | -302.42 | -244.98 | -200.38 | -159.96 | -94.01 |
Comprehensive Income & Other | -0.36 | 0.09 | 0 | -0.03 | -0.69 | -0.21 |
Shareholders' Equity | 161.31 | 196.41 | 167.13 | 68.32 | 102.08 | 161.91 |
Total Liabilities & Equity | 176.09 | 209.47 | 181.45 | 78.95 | 113.29 | 172.6 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 2.75 | 3.36 | 4.48 | 5.47 | 6.38 | 7.24 |
Net Cash (Debt) | 159.1 | 194.53 | 165.81 | 60.11 | 95.87 | 123.46 |
Net Cash Growth | 12.31% | 17.32% | 175.83% | -37.30% | -22.34% | -26.30% |
Net Cash Per Share | 3.08 | 4.54 | 8.05 | 5.31 | 8.51 | 10.99 |
Filing Date Shares Outstanding | 59.1 | 54.08 | 36.77 | 11.43 | 11.31 | 11.25 |
Total Common Shares Outstanding | 59.08 | 53.59 | 35.04 | 11.36 | 11.27 | 11.24 |
Working Capital | 132.83 | 148.57 | 161.19 | 62.56 | 80.41 | 88.81 |
Book Value Per Share | 2.73 | 3.67 | 4.77 | 6.01 | 9.06 | 14.41 |
Tangible Book Value | 161.31 | 196.41 | 167.13 | 68.32 | 102.08 | 132.4 |
Tangible Book Value Per Share | 2.73 | 3.67 | 4.77 | 6.01 | 9.06 | 11.78 |
Machinery | - | 1.67 | 1.5 | 1.51 | 1.42 | 1.12 |
Leasehold Improvements | - | 0.55 | 0.55 | 0.55 | 0.55 | 0.22 |